U.S. External and Implantable Cardiac Defibrillators Market to Reach USD 4.32 Billion by 2030, Led by Boston Scientific, Medtronic, and Abbott

The U.S. External and Implantable Cardiac Defibrillators Market was valued at US$ 2.64 billion in 2023 and is projected to reach US$ 4.32 billion by 2030, growing at a CAGR of 7.3% during 2024-2030. Market expansion is supported by the rising prevalence of sudden cardiac arrest, growing adoption of advanced defibrillation technologies, and increased deployment of external defibrillators across hospitals, public facilities, and emergency response systems.

The market holds a strong position within the U.S. cardiovascular devices sector, with implantable cardioverter defibrillators contributing a major share due to their proven effectiveness in preventing fatal arrhythmias. External defibrillators, including automated and wearable devices, continue to gain momentum with widespread public-access initiatives and healthcare modernization. The integration of digital monitoring, real-time diagnostics, and next-generation therapeutic technologies is expected to reinforce steady long-term market growth.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/external-and-implantable-cardiac-defibrillators-market?sai-v

The External and Implantable Cardiac Defibrillators Market involves medical devices designed to detect and correct life-threatening cardiac arrhythmias by delivering controlled electric shocks to restore normal heart rhythm.

Key Developments

United States

✅ May 2025: The FDA approved Element Science's AI-enabled Jewel Patch wearable cardioverter defibrillator (WCD), a slim patch-style device designed for continuous arrhythmia detection and on-patch therapy delivery.

✅ April 2025: Medtronic received regulatory clearance for an updated defibrillation lead design (OmniaSecure), emphasizing smaller form factor and improved longevity to reduce implantation risks.

✅ Feb-Mar 2025: Clinical and commercial momentum continued for subcutaneous ICDs (S-ICDs) and wearable defibrillators as hospitals and electrophysiology centres expanded adoption to reduce transvenous-lead complications.

Japan

✅ May 2025: Japan Lifeline reported double-digit year-over-year growth in S-ICD sales, reflecting broader physician uptake and expanded access through additional electrophysiology centres.

✅ March 2025: The TRANSITION-JAPAN observational study launched across multiple centres to assess clinical outcomes for patients using wearable and implantable defibrillators, strengthening domestic evidence generation.

✅ Jan-Mar 2025: Japanese clinical and guideline activity accelerated - professional societies incorporated genetic-risk markers into ICD patient-selection guidance and hospitals increased implantation programs for high-risk patients.

Key Players:

Koninklijke Philips N.V. | Nihon Kohden Corporation | Medtronic plc | Boston Scientific Corporation | Stryker Corporation | ZOLL Medical Corporation | Abbott Laboratories | MicroPort Medical Products Ltd. | LivaNova PLC | Mindray Medical India Pvt. Ltd.

Key Highlights :
• Koninklijke Philips N.V. - Reported EUR 18.2 billion in 2024 revenue, supported by strong performance in image-guided therapy, connected care, and patient monitoring systems.

• Nihon Kohden Corporation - Achieved JPY 220+ billion in annual revenue, driven by growth in patient monitoring, diagnostic cardiology, and emergency care devices globally.

• Medtronic plc - Posted USD 31.2 billion in FY 2024 revenue, maintaining global leadership in cardiac care, neuromodulation, monitoring, and life-saving medical technologies.

• Boston Scientific Corporation - Recorded USD 14.7 billion in 2024 sales, propelled by strong growth in cardiac rhythm management, electrophysiology, and minimally invasive surgical devices.

• Stryker Corporation - Generated USD 21.3 billion in 2024 revenue, driven by robust demand for medical devices across emergency care, neurotechnology, and monitoring solutions.

• ZOLL Medical Corporation - A key global provider of defibrillation and emergency care technologies; operates under Asahi Kasei with strong multi-billion-dollar revenue contribution (specific ZOLL figures not publicly disclosed).

• Abbott Laboratories - Reported USD 40.1 billion in 2024 revenue, with strong growth from its cardiovascular, electrophysiology, and diagnostics divisions.

• MicroPort Medical Products Ltd. - Part of MicroPort Scientific Corporation, which reported USD 1.4+ billion in revenue, led by cardiac rhythm management and interventional cardiology systems.

• LivaNova PLC - Delivered USD 1.1 billion in annual revenue, supported by strong cardiovascular solutions and neuromodulation therapy products.

• Mindray Medical India Pvt. Ltd. - A subsidiary of Mindray; parent company Mindray reported CNY 34+ billion in revenue, with expanding presence in patient monitoring, life-support systems, and diagnostic solutions across India and global markets.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=external-and-implantable-cardiac-defibrillators-market?sai-v

Market Drivers & Growth

- Increasing prevalence of cardiovascular diseases, including arrhythmias and sudden cardiac arrest, is driving strong demand for both external and implantable defibrillators.

- Rising geriatric population and lifestyle-related risk factors-hypertension, obesity, diabetes-are contributing to higher adoption.

- Growth in emergency care infrastructure and improved availability of automated external defibrillators (AEDs) in public and commercial spaces is supporting market expansion.

- Technological improvements such as smaller device sizes, enhanced battery life, wireless monitoring, and better shock-delivery algorithms are boosting adoption.

- Increasing awareness programs and government initiatives to install AEDs in airports, malls, schools, and workplaces are strengthening market growth.

Industrial Advances & Developments

- Development of lightweight, wearable defibrillators designed for high-risk patients who are not yet candidates for implants.

- Innovations in implantable cardioverter defibrillators (ICDs) including MRI-compatible devices, lead-less systems, and subcutaneous ICDs that reduce complications.

- Cloud-enabled remote monitoring platforms that allow real-time tracking of cardiac events and device performance.

- Integration of advanced arrhythmia detection algorithms that improve accuracy and reduce inappropriate shocks.

- Strategic collaborations between device manufacturers, hospitals, and research institutes to enhance clinical outcomes and accelerate product advancements.

Regional Insights

- North America: Leading market driven by advanced healthcare infrastructure, high cardiovascular disease burden, and strong adoption of ICDs and AEDs.

- Europe: Strong growth supported by public AED installation programs, strict cardiac care guidelines, and well-established hospital networks.

- Asia-Pacific: Fastest-growing region due to rising awareness of cardiac emergencies, improving healthcare access, and increasing adoption of AEDs in public spaces.

- Latin America: Moderate growth driven by expanding private healthcare sector and rising investment in emergency response systems.

- Middle East & Africa: Growing adoption supported by modernizing hospitals and government initiatives to improve cardiac care capabilities.

Key Segments:

➥ By Product Type
Implantable Cardioverter Defibrillators (ICDs) lead the market due to their effectiveness in preventing sudden cardiac arrest in high-risk patients. External defibrillators, including AEDs, continue to grow rapidly with rising public awareness, workplace installations, and emergency response adoption.

➥ By Patient Type
Adults account for the majority of demand due to higher prevalence of cardiac disorders and arrhythmias. Pediatrics represent a smaller but important segment, with increasing focus on early diagnosis and specialized defibrillation solutions for children.

➥ By End-User
Hospitals remain the dominant end-users owing to advanced cardiac care infrastructure and emergency treatment needs. Specialty clinics show steady growth with expanding cardiology services. Home healthcare adoption rises as home-based cardiac monitoring and chronic disease management become more common. Other settings, including public spaces and ambulances, increasingly deploy external defibrillators for rapid emergency respon

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/external-and-implantable-cardiac-defibrillators-market?sai-v

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.